One in Five MS Patients Misdiagnosed One in Five MS Patients Misdiagnosed
Multiple sclerosis misdiagnosis is associated with considerable patient risk and immense healthcare cost through the inappropriate prescribing of drug treatments, authors of a new study say.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 18, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

OHSU study offers hope for people with multiple sclerosis
In multiple sclerosis, the immune system eats away at the sheath that protects the nerves, disrupting signals between the brain and the body and causing problems in walking and eyesight. No drugs have ever been developed to restore that protective layer, called myelin. But a study out Thursday from Oregon Health& Science University offers some hope. Researchers found myelin repair is possible, though their method has not yet been tested in humans. The potential game changer is a compound called… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 18, 2019 Category: American Health Authors: Elizabeth Hayes Source Type: news

Brain activation changes during balance- and attention-demanding tasks in middle- and older-aged adults with multiple sclerosis - Hernandez ME, O'Donnell E, Chaparro G, Holtzer R, Izzetoglu M, Sandroff BM, Motl RW.
Functional near-infrared spectroscopy was used to evaluate prefrontal cortex activation differences between older adults with multiple sclerosis (MS) and healthy older adults (HOA) during the performance of a balance- and attention-demanding motor task. Te... (Source: SafetyLit)
Source: SafetyLit - April 18, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Vitamin D study sheds light on immune system effects
(University of Edinburgh) Scientists at the University of Edinburgh have uncovered fresh insights into how vitamin D affects the immune system and might influence susceptibility to diseases such as multiple sclerosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2019 Category: International Medicine & Public Health Source Type: news

Measuring brain activity in milliseconds possible through new research
(King's College London) Researchers from King's College London, Harvard and INSERM-Paris have discovered a new way to measure brain function in milliseconds using magnetic resonance elastography (MRE). This could help with diagnosing and understanding neurological diseases like Alzheimer's, dementia, multiple sclerosis, or epilepsy. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 17, 2019 Category: International Medicine & Public Health Source Type: news

Comparing the benefits of Tai Chi and meditation on MS symptoms
(University of Massachusetts at Amherst) Kinesiology researchers at the University of Massachusetts Amherst have received funding to compare the effects of tai chi and mindfulness meditation on both the physical balance and psychosocial well-being of people with multiple sclerosis (MS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 16, 2019 Category: International Medicine & Public Health Source Type: news

Sanofi MS drug under safety review in the EU for dangerous side effects
The European Medicines Agency is taking a closer look at safety issues linked to the use of a Sanofi multiple sclerosis drug, Lemtrada. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 15, 2019 Category: Pharmaceuticals Source Type: news

Obesity a Key Driver of Multiple Sclerosis Risk Obesity a Key Driver of Multiple Sclerosis Risk
Ties between early puberty and an increased risk for multiple sclerosis appear to be largely driven by increased body weight, supporting the need for obesity prevention efforts.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 12, 2019 Category: Endocrinology Tags: Neurology & Neurosurgery News Source Type: news

Medical News Today: Signs and symptoms of MS in women
Multiple sclerosis (MS) is a disease that damages the nerves and causes a wide range of symptoms, including vision problems and numbness. In this article, learn about the symptoms of MS in women. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 12, 2019 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

Many Misdiagnosed With MS
THURSDAY, April 11, 2019 -- Almost one in five multiple sclerosis patients may be misdiagnosed with the autoimmune disease, according to a new study. Of 241 previously diagnosed multiple sclerosis (MS) patients referred to two major Los Angeles... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 11, 2019 Category: General Medicine Source Type: news

Body mass index may play a significant role in the progression of multiple sclerosis
(Advanced Science Research Center, GC/CUNY) A newly published paper in the Lancet journal EBioMedicine identifies a link between high levels of blood lipids and worsening of disease in multiple sclerosis (MS) patients who are overweight or obese. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2019 Category: International Medicine & Public Health Source Type: news

Wikipedia: The new inquisition
(Natural News) Consider: you are given a serious diagnosis – cancer, dementia, multiple sclerosis – and your doctor runs you through the standard treatment protocol. It fails to reverse or cure the condition, leaving you hundreds of thousands of dollars poorer and sicker. It’s time to explore your options, you decide, and seek out others... (Source: NaturalNews.com)
Source: NaturalNews.com - April 9, 2019 Category: Consumer Health News Source Type: news

Cortical Lesions in Multiple Sclerosis Tracked With 7.0-T MRI
TUESDAY, April 9, 2019 -- Cortical lesion development surpasses white matter lesion accrual in multiple sclerosis (MS), according to a study published online April 9 in Radiology. Constantina A. Treaba, M.D., Ph.D., from Massachusetts General... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2019 Category: Pharmaceuticals Source Type: news

7T MRI shows path to MS progression
Add another clue for unraveling the mystery that is multiple sclerosis (MS)....Read more on AuntMinnie.comRelated Reading: 7T finds epilepsy abnormalities missed at lower field strengths Contrast not needed for follow-up MRI on MS patients Deep-learning MRI algorithm aids in neurological diagnoses Is 7-tesla MRI ready yet to go clinical? Can 7-tesla MRI make the transition to clinical prime time? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 9, 2019 Category: Radiology Source Type: news

No Influence of Dietary, Supplemental Minerals on MS Risk No Influence of Dietary, Supplemental Minerals on MS Risk
Potassium, magnesium, calcium, and other minerals neither guard against or promote the risk of multiple sclerosis, new research shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 8, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Minerals Not Linked to Multiple Sclerosis Risk in Women
WEDNESDAY, April 3, 2019 -- Mineral intake seems not to be associated with the risk for multiple sclerosis (MS) among women, according to a study published online April 3 in Neurology. Marianna Cortese, M.D., Ph.D., from the Harvard T.H. Chan School... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2019 Category: Pharmaceuticals Source Type: news

Beta Interferon Tied to Lower Mortality in Relapsing-Onset MS
WEDNESDAY, April 3, 2019 -- For patients with relapsing-onset multiple sclerosis, beta interferon treatment is associated with a lower mortality risk, according to a study published online March 18 in Brain. Elaine Kingwell, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Mavenclad for Treating Multiple Sclerosis
MONDAY, April 1, 2019 -- Mavenclad (cladribine) tablets were approved to treat adult patients with relapsing-remitting and active secondary progressive multiple sclerosis (MS) who have inadequately responded to or cannot tolerate an alternate drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2019 Category: Pharmaceuticals Source Type: news

Mavenclad Approved for Multiple Sclerosis
MONDAY, April 1, 2019 -- Mavenclad (cladribine) tablets have been approved by the U.S. Food and Drug Administration to treat relapsing multiple sclerosis (MS) in adults. An agency news release said the drug is recommended for people who have had an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 1, 2019 Category: General Medicine Source Type: news

Second New MS Drug Mavenclad (Cladribine) Secures FDA Approval
MONDAY, April 1, 2019 -- The U.S. Food and Drug Administration has approved another new multiple sclerosis drug -- the second in one week. Mavenclad (cladribine) pills can be used to treat relapsing forms of MS in adults, including... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 1, 2019 Category: General Medicine Source Type: news

Second New MS Drug Secures FDA Approval
MONDAY, April 1, 2019 -- The U.S. Food and Drug Administration has approved another new multiple sclerosis drug -- the second in one week. Mavenclad (cladribine) pills can be used to treat relapsing forms of MS in adults, including... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 1, 2019 Category: General Medicine Source Type: news

Containing the escalating costs of prescription drug benefits
What ’s one of the fastest growing components of health care costs? Prescription drug benefits, and in particular, specialty drugs that are increasingly prescribed by doctors. Specialty drugs are high-cost prescription medications used to treat complex chronic conditions like cancer, rheumatoid arthr itis and multiple sclerosis. Ten years ago, specialty prescription drugs represented only 13% of pharmacy spend, but that percentage is projected to jump to 50% by 2020. While specialty medications… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 1, 2019 Category: Health Management Authors: Alan Ikeya and Brian Hegarty Source Type: news

Containing the escalating costs of prescription drug benefits
What ’s one of the fastest growing components of health care costs? Prescription drug benefits, and in particular, specialty drugs that are increasingly prescribed by doctors. Specialty drugs are high-cost prescription medications used to treat complex chronic conditions like cancer, rheumatoid arthr itis and multiple sclerosis. Ten years ago, specialty prescription drugs represented only 13% of pharmacy spend, but that percentage is projected to jump to 50% by 2020. While specialty medications… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 1, 2019 Category: Biotechnology Authors: Alan Ikeya and Brian Hegarty Source Type: news

Merck KGaA gets FDA nod for MS med
The U.S. FDA has approved EMD Serono's Mavenclad tablets for the treatment of relapsing forms of multiple sclerosis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 1, 2019 Category: Pharmaceuticals Source Type: news

Serving Selflessly Gives Residents ’ Lives Meaning
Are we seeing the disability or the potential? Residents with challenges such as Alzheimer ’s disease, stroke, Parkinson’s disease, multiple sclerosis, or vision impairment prepare meals and feed the homeless throughout California. (Source: Caring for the Ages)
Source: Caring for the Ages - April 1, 2019 Category: Health Management Authors: Matthew Lysobey Tags: Innovations in PALTC Source Type: news

Monthly News Roundup - March 2019
Mayzent First Oral Treatment Approved for Active Secondary Progressive MS In March the U.S. Food and Drug Administration (FDA) approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), which includes... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Cladribine (Mavenclad) for Relapsing MS FDA Approves Cladribine (Mavenclad) for Relapsing MS
The US Food and Drug Administration today approved cladribine for treatment of patients with relapsing multiple sclerosis who have had insufficient response to other agents.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 30, 2019 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news

Wheelchair-assisted ligature strangulation: an unusual suicide by a quadriparetic - Janik M, Krajcovic J, Novomesky F, Straka L, Hejna P.
Multiple sclerosis, currently incurable and potentially profoundly disabling demyelinating central nervous system disease, is associated with higher occurrence of suicide as affected individuals are prone to major depression and psychosis. Despite progress... (Source: SafetyLit)
Source: SafetyLit - March 30, 2019 Category: International Medicine & Public Health Tags: Drowning, Suffocation Source Type: news

FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis
March 29, 2019 -- The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves new oral treatment for multiple sclerosis
FDA approves Mayzent (cladribine), a new oral drug to treat multiple sclerosis (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 29, 2019 Category: American Health Source Type: news

Common MS Treatment, Beta Interferon, Can Bring Longer, Healthier Life
THURSDAY, March 28, 2019 -- An older but still common multiple sclerosis (MS) treatment has an unexpected perk: It not only quells symptoms, but patients may also live longer. New research revealed that patients taking a beta interferon drug for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2019 Category: General Medicine Source Type: news

Common MS Treatment Can Bring Longer, Healthier Life
THURSDAY, March 28, 2019 -- An older but still common multiple sclerosis (MS) treatment has an unexpected perk: It not only quells symptoms, but patients may also live longer. New research revealed that patients taking a beta interferon drug for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2019 Category: General Medicine Source Type: news

Novartis MS drug wins FDA's blessing amid scrutiny of $88,000 annual price
Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Mayzent Approved for Relapsing MS
WEDNESDAY, March 27, 2019 -- Mayzent (siponimod) pills have been approved by the U.S. Food and Drug Administration for adults with relapsing multiple sclerosis (MS). " Multiple sclerosis can have a profound impact on a person's life, " said Dr. Billy... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2019 Category: General Medicine Source Type: news

FDA OKs Mayzent (siponimod) for Multiple Sclerosis
WEDNESDAY, March 27, 2019 -- A new pill for relapsing forms of multiple sclerosis (MS) has won approval from the U.S. Food and Drug Administration. Generally, relapsing MS involves periods of worsening symptoms followed by recovery periods. Over... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2019 Category: General Medicine Source Type: news

Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis (SPMS) in adults Up to 80% of patients with relapsing remitting MS (RRMS) will develop SPMS(1); Mayzent addresses a ... Biopharmaceuticals, Neurology, FDA Novartis, Mayzent, siponimod, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Mayzent for Relapsing Multiple Sclerosis
WEDNESDAY, March 27, 2019 -- Mayzent (siponimod) pills have been approved by the U.S. Food and Drug Administration for adults with relapsing multiple sclerosis. Mayzent's effectiveness was shown in clinical studies of 1,651 patients. Progression of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 27, 2019 Category: Pharmaceuticals Source Type: news

Novartis receives FDA approval for Mayzent ® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS)*. (Source: World Pharma News)
Source: World Pharma News - March 27, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novartis gets U.S. approval for new drug to treat multiple sclerosis
Novartis AG won U.S. Food and Drug Administration approval for its new multiple sclerosis drug Mayzent, as the Swiss drugmaker seeks to tap a new group of patients in whom the neurological disease has shifted from intermittent attacks to a gradually worsening progression. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Siponimod (Mayzent) for Multiple Sclerosis FDA Approves Siponimod (Mayzent) for Multiple Sclerosis
The agency has approved a new oral agent for relapsing forms of multiple sclerosis, including clinically isolated syndrome and secondary progressive disease.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 27, 2019 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news

Novartis new MS drug Mayzent to be priced at $88,000 per year
Novartis will price its new Mayzent multiple sclerosis drug at $88,000 dollars per year, the Swiss company's head of pharmaceuticals, Paul Hudson, said. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Siponimod (Mayzent) for Multiple Sclerosis
FDA Approves Siponimod (Mayzent) for Multiple Sclerosis (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 27, 2019 Category: General Medicine Source Type: news

FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis
Basel, March 27, 2019 - Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary progressive multiple... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 27, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves new oral drug to treat multiple sclerosis
The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2019 Category: American Health Source Type: news

New Partnership Forms to Develop Breakthrough Neuromodulation Device
WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device. The new MyoRegulator PM-200 provides a non-invasive treatment option for patients suffering from muscle spasticity, a common condition found in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury, and traumatic...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Kristopher Sturgis Tags: Business Source Type: news

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
SUMMIT, N.J.--(BUSINESS WIRE)--March 25, 2019 Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 25, 2019 Category: Drugs & Pharmacology Source Type: news

Multiple sclerosis patients' brains cells are DECADES older than they should be   
MS hit the headlines last October when the actress Selma Blair (pictured) went public about her diagnosis after years of 'self medicating'. The study was carried out by the University of Connecticut. (Source: the Mail online | Health)
Source: the Mail online | Health - March 25, 2019 Category: Consumer Health News Source Type: news

Here ’s Everything You Need to Know About Gut Health
It’s hardly news that the gastrointestinal tract is important to human health: It transports food from the mouth to the stomach, converts it into absorbable nutrients and stored energy, and shuttles waste back out of the body. If you don’t properly nourish yourself, you don’t live. It’s that simple. But in recent years, scientists have discovered that the GI system has an even bigger, more complex job than previously appreciated. It’s been linked to numerous aspects of health that have seemingly nothing to do with digestion, from immunity to emotional stress to chronic illnesses, including can...
Source: TIME: Health - March 25, 2019 Category: Consumer Health News Authors: Amanda MacMillan Tags: Uncategorized Research Source Type: news

Pace of Multiple Sclerosis Progression May Be Slowing Pace of Multiple Sclerosis Progression May Be Slowing
The risk for reaching specific disability milestones in patients with multiple sclerosis has decreased over the past decade, a large cohort study from Sweden suggests.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 22, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Managing MS
FRIDAY, March 22, 2019 -- Proper treatment can help people with multiple sclerosis (MS) contend with their disease, an expert says. " Patients get a predisposed feeling that their life is doomed. That it's going to be a complicated life, which isn't... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2019 Category: General Medicine Source Type: news